Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.16−0.27 (-6.09%)
Close on Nov 12, 2026Market cap $443.75MP/E –Yield –
Relmada Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Relmada Therapeutics's enterprise value was $254.82M on Nov 11, 2026, against $135.81M a year earlier. Over the last 5 years it ranged from -$179.08M to $867.84M, with a median of $27.33M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $254.82M | +74.0% |
| 2025 | Dec 31, 2025 | $146.43M | – |
| 2024 | Dec 31, 2024 | -$38.43M | -309.5% |
| 2023 | Dec 29, 2023 | $18.34M | – |
| 2022 | Dec 30, 2022 | -$179.08M | -158.5% |
| 2021 | Dec 31, 2021 | $306.22M | +1.0% |
| 2020 | Dec 31, 2020 | $303.29M | -18.2% |
| 2019 | Dec 31, 2019 | $370.82M | +2115.5% |
| 2018 | Dec 31, 2018 | $16.74M | +209.8% |
| 2017 | Dec 29, 2017 | $5.40M | -21.7% |
| 2016 | Dec 30, 2016 | $6.90M | -17.6% |
| 2015 | Dec 31, 2015 | $8.37M | -29.4% |
| 2014 | Dec 31, 2014 | $11.85M | – |
See a number that looks wrong?